1. Functionalized azirine based scaffolds as endothelin inhibitors for the selective anti-angiogenic activity.
- Author
-
Singh H, Satish N, Babu TR, Singh A, Yadav B, Singh SK, Wahajuddin M, Siddiqui MI, Jagavelu K, and Sudhakar G
- Subjects
- Humans, Animals, Mice, Structure-Activity Relationship, Molecular Structure, Dose-Response Relationship, Drug, Cell Proliferation drug effects, Cell Movement drug effects, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antineoplastic Agents chemical synthesis, Neovascularization, Pathologic drug therapy, Angiogenesis Inhibitors pharmacology, Angiogenesis Inhibitors chemistry, Angiogenesis Inhibitors chemical synthesis, Human Umbilical Vein Endothelial Cells drug effects, Azirines chemistry, Azirines pharmacology, Azirines chemical synthesis
- Abstract
Anti-angiogenic therapy has long been used as an adjunct therapy for the resolution of tumor burden. The current findings describe the synthesis of novel marine-based azirine-containing compounds that exhibit anti-angiogenic mediated anti-tumor activity. Azirine-2-carboxylate inhibited HUVEC-mediated tubulogenesis without causing cell death in a dose-dependent manner. Ex-vivo CAM, in-vivo Matrigel implantation, and ear angiogenesis experiments have all shown that azirine-2-carboxylate effectively inhibits angiogenesis. Furthermore, azirine-2-carboxylate inhibits the migration of ECs without disrupting the preformed tubule network. Azirine-2-carboxylate had adequate intramuscular systemic exposure and inhibited tumor growth in a xenograft mouse model. DARTS analysis, competitive binding assay, and gene expression investigations revealed that azirine-2-carboxylate inhibits endothelin-1-mediated angiogenesis. Overall, the discovery of azirine-2-carboxylate demonstrated a potent inhibition of angiogenesis targeting ET1 and a possible application in anti-angiogenic therapy., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Gangarajula Sudhakar reports was provided by Ministry of Earth Sciences. Dr. Gangarajula Sudhakar has patent pending to Assignee (CSIR-India). If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Masson SAS. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF